Deal Lab · Buyout model 1.0
Eli Lilly and Company Buyout Model
The buyout model of Eli Lilly and Company on its published figures, in US dollars.
Inputs Missing
The model of this company does not run on its published figures, which leave out the following. No figure stands in for a missing input.
- Capital expenditure: no capital expenditure is published for the last 3 fiscal years.
Inputs and Their Documents
Published figures of fiscal 2024, each with the documents it comes from.
| Input | Value | Method | Documents |
|---|---|---|---|
| Adjusted EBITDA | $16.1bn | Adjusted EBITDA of the company page | 10-K 2025-12, 10-K 2024-12 |
| Share-based pay | $646m | Share-based pay that adjusted EBITDA adds back | 10-K 2025-12 |
| EBITDA after share-based pay | $15.4bn | Adjusted EBITDA less share-based pay | 10-K 2025-12, 10-K 2024-12 |
| Depreciation and amortisation | $1.8bn | Depreciation and amortisation of adjusted EBITDA | 10-K 2025-12 |
| Revenue | $45.0bn | Revenue of the base period | 10-K 2024-12, 10-K 2025-12 |
| Operating lease cost | $210m | Operating lease cost | 10-K 2024-12 |
| Borrowings | $33.6bn | Total debt less lease liabilities | 10-K 2025-12, 10-K 2024-12 |
| Lease liabilities | $1.1bn | Lease liabilities | 10-K 2024-12 |
| Cash and short-term investments | $3.4bn | Cash and short-term investments | 10-K 2024-12, 10-K 2025-12, 10-Q 2025-09 |
| Non-controlling interests | $79.5m | Non-controlling interests | 10-K 2024-12, 10-K 2025-12, 10-Q 2025-09 |
| Receivables | $11.0bn | Receivables | 10-K 2024-12, 10-K 2025-12, 10-Q 2025-09 |
| Payables | $3.2bn | Payables | 10-K 2024-12, 10-K 2025-12, 10-Q 2025-09 |
| Inventories | $7.6bn | Inventories | 10-K 2024-12, 10-K 2025-12, 10-Q 2025-09 |
Deal Lab computes arithmetic on published figures and on the assumptions of the user. It values no company, recommends no transaction and forecasts no result.